API Holdings (Pharmeasy) Unlisted Shares
API Holdings valuation plummets 90% following oversubscribed rights issue
investing.com
2 min read
API Holdings' Valuation Falls to $500 Million Post Oversubscribed Rights Issue, Focuses on Profitability by April 2023
Expert Analysis:
API Holdings, parent to health tech firms like PharmEasy and Thyrocare Technologies, saw its valuation plummet by 90%.
A ₹3,500 crore rights issue set the share price at ₹5, reducing the company's worth to $500 million from its peak of $5.6 billion.
This was primarily to service debt to Goldman Sachs, a move supported by key investors.
Despite the sharp valuation drop, API Holdings maintains confidence in future profitability, targeting April 2023 for profitability with an estimated cumulative EBITDA of ₹60 crore.
Valuation Plunge: API Holdings' Worth Falls to $500 Million Post ₹3,500 Crore Rights Issue
Debt-Targeted Move: Purpose of the Valuation Drop to Fulfill Goldman Sachs Obligations Gains Investor Support
Profitability Focus: Despite Reduced Valuation, API Holdings Aims to Achieve Profitability by April 2023
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved